Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial
R Trepiakas, A Berntsen, SR Hadrup, J Bjørn… - Cytotherapy, 2010 - Elsevier
Background aims Dendritic cells are regarded as the most effective antigen presenting cells
and coordinators of the immune response and therefore suitable as vaccine basis. Here we
present results from a clinical study in which patients with malignant melanoma (MM) with
verified progressive disease received vaccination with autologous monocyte-derived mature
dendritic cells (DC) pulsed with p53, survivin and telomerase-derived peptides (HLA-A2+
patients) or with autologous/allogeneic tumor lysate (HLA-A2− patients) in combination with …
and coordinators of the immune response and therefore suitable as vaccine basis. Here we
present results from a clinical study in which patients with malignant melanoma (MM) with
verified progressive disease received vaccination with autologous monocyte-derived mature
dendritic cells (DC) pulsed with p53, survivin and telomerase-derived peptides (HLA-A2+
patients) or with autologous/allogeneic tumor lysate (HLA-A2− patients) in combination with …